Serologic evolution of neurocysticercosis patients after antiparasitic therapy

H. H. Garcia; R. H. Gilman; M. Catacora; M. Verastegui; A. E. Gonzalez; V. C.W. Tsang; M. Martinez; J. Altamirano; L. Trelles; J. M. Cuba; M. Alvarado; G. Alban; H. Estrada; N. Rios-Saavedra; M. Soto; M. P. Torres; J. Boero; C. Gavidia; E. Barron

doi:10.1093/infdis/175.2.486

Serologic evolution of neurocysticercosis patients after antiparasitic therapy

H. H. Garcia, R. H. Gilman, M. Catacora, M. Verastegui, A. E. Gonzalez, V. C.W. Tsang, M. Martinez, J. Altamirano, L. Trelles, J. M. Cuba, M. Alvarado, G. Alban, H. Estrada, N. Rios-Saavedra, M. Soto, M. P. Torres, J. Boero, C. Gavidia, E. Barron

Research output: Contribution to journal › Article › peer-review

79 Scopus citations

Abstract

Neurocysticercosis is the main cause of acquired epilepsy in developing countries and is an emerging disease in the United States. Introduction of the immunoblot assay provided a new tool for the diagnosis and monitoring of neurocysticercosis. This study analyzed the relationship between clinical characteristics of cerebral infection (number and type of lesions) plus the baseline response on immunoblot and the changes observed after therapy. Reaction to all 7 diagnostic bands was associated with severe infection (more lesions). Seventeen patients (35%) had no active lesions on computed tomography (CT) 3 months after therapy and were considered cured. Although most cured patients remained seropositive after 1 year, 3 became seronegative before 9 months. In these 3 cases, the lesions had resolved on CT at 3 months. Persistent seropositivity does not necessarily indicate active infection. Serologic follow-up will be clinically helpful only in rare cases in which early antibody disappearance occurs.

Original language	English
Pages (from-to)	486-489
Number of pages	4
Journal	Journal of Infectious Diseases
Volume	175
Issue number	2
DOIs	https://doi.org/10.1093/infdis/175.2.486
State	Published - 1997

Bibliographical note

Funding Information:
Financial support: Institut Malarde and UNDP/World BanklWHO Special Programme for Research and Training in Tropical Diseases, Task Force on Operational Research on Filariasis.

Funding Information:
Received 8 July 1996; revised 23 September 1996. Informed consent was obtained from all patients, and the study was approved by the ethical review boards of the Universidad Peruana Cayetano Heredia and Johns Hopkins University. Financial support: NIH (AI-35894) and SmithKline Beecham Pharmaceuticals (London). Correspondence: Dr. R. H. Gilman, Dept. of International Health, School of Hygiene and Public Health, Johns Hopkins University, 615 N. Wolfe St., Baltimore, MD 21205. Reprints: Dr. H. H. Garcia, Dept. de Microbiologia, Universidad Peruana Cayetano Heredia, Av. Honorio Delgado 430, Lima 31, Peru. * Members are listed after the text.

Access to Document

10.1093/infdis/175.2.486

Cite this

Garcia, H. H., Gilman, R. H., Catacora, M., Verastegui, M., Gonzalez, A. E., Tsang, V. C. W., Martinez, M., Altamirano, J., Trelles, L., Cuba, J. M., Alvarado, M., Alban, G., Estrada, H., Rios-Saavedra, N., Soto, M., Torres, M. P., Boero, J., Gavidia, C., & Barron, E. (1997). Serologic evolution of neurocysticercosis patients after antiparasitic therapy. Journal of Infectious Diseases, 175(2), 486-489. https://doi.org/10.1093/infdis/175.2.486

@article{7ee0dd5c711448078818c06b54c8cbfd,

title = "Serologic evolution of neurocysticercosis patients after antiparasitic therapy",

abstract = "Neurocysticercosis is the main cause of acquired epilepsy in developing countries and is an emerging disease in the United States. Introduction of the immunoblot assay provided a new tool for the diagnosis and monitoring of neurocysticercosis. This study analyzed the relationship between clinical characteristics of cerebral infection (number and type of lesions) plus the baseline response on immunoblot and the changes observed after therapy. Reaction to all 7 diagnostic bands was associated with severe infection (more lesions). Seventeen patients (35%) had no active lesions on computed tomography (CT) 3 months after therapy and were considered cured. Although most cured patients remained seropositive after 1 year, 3 became seronegative before 9 months. In these 3 cases, the lesions had resolved on CT at 3 months. Persistent seropositivity does not necessarily indicate active infection. Serologic follow-up will be clinically helpful only in rare cases in which early antibody disappearance occurs.",

author = "Garcia, {H. H.} and Gilman, {R. H.} and M. Catacora and M. Verastegui and Gonzalez, {A. E.} and Tsang, {V. C.W.} and M. Martinez and J. Altamirano and L. Trelles and Cuba, {J. M.} and M. Alvarado and G. Alban and H. Estrada and N. Rios-Saavedra and M. Soto and Torres, {M. P.} and J. Boero and C. Gavidia and E. Barron",

note = "Funding Information: Financial support: Institut Malarde and UNDP/World BanklWHO Special Programme for Research and Training in Tropical Diseases, Task Force on Operational Research on Filariasis. Funding Information: Received 8 July 1996; revised 23 September 1996. Informed consent was obtained from all patients, and the study was approved by the ethical review boards of the Universidad Peruana Cayetano Heredia and Johns Hopkins University. Financial support: NIH (AI-35894) and SmithKline Beecham Pharmaceuticals (London). Correspondence: Dr. R. H. Gilman, Dept. of International Health, School of Hygiene and Public Health, Johns Hopkins University, 615 N. Wolfe St., Baltimore, MD 21205. Reprints: Dr. H. H. Garcia, Dept. de Microbiologia, Universidad Peruana Cayetano Heredia, Av. Honorio Delgado 430, Lima 31, Peru. * Members are listed after the text.",

year = "1997",

doi = "10.1093/infdis/175.2.486",

language = "Ingl{\'e}s",

volume = "175",

pages = "486--489",

journal = "Journal of Infectious Diseases",

issn = "0022-1899",

publisher = "Oxford University Press",

number = "2",

}

Garcia, HH, Gilman, RH, Catacora, M, Verastegui, M, Gonzalez, AE, Tsang, VCW, Martinez, M, Altamirano, J, Trelles, L, Cuba, JM, Alvarado, M, Alban, G, Estrada, H, Rios-Saavedra, N, Soto, M, Torres, MP, Boero, J, Gavidia, C & Barron, E 1997, 'Serologic evolution of neurocysticercosis patients after antiparasitic therapy', Journal of Infectious Diseases, vol. 175, no. 2, pp. 486-489. https://doi.org/10.1093/infdis/175.2.486

TY - JOUR

T1 - Serologic evolution of neurocysticercosis patients after antiparasitic therapy

AU - Garcia, H. H.

AU - Gilman, R. H.

AU - Catacora, M.

AU - Verastegui, M.

AU - Gonzalez, A. E.

AU - Tsang, V. C.W.

AU - Martinez, M.

AU - Altamirano, J.

AU - Trelles, L.

AU - Cuba, J. M.

AU - Alvarado, M.

AU - Alban, G.

AU - Estrada, H.

AU - Rios-Saavedra, N.

AU - Soto, M.

AU - Torres, M. P.

AU - Boero, J.

AU - Gavidia, C.

AU - Barron, E.

N1 - Funding Information: Financial support: Institut Malarde and UNDP/World BanklWHO Special Programme for Research and Training in Tropical Diseases, Task Force on Operational Research on Filariasis. Funding Information: Received 8 July 1996; revised 23 September 1996. Informed consent was obtained from all patients, and the study was approved by the ethical review boards of the Universidad Peruana Cayetano Heredia and Johns Hopkins University. Financial support: NIH (AI-35894) and SmithKline Beecham Pharmaceuticals (London). Correspondence: Dr. R. H. Gilman, Dept. of International Health, School of Hygiene and Public Health, Johns Hopkins University, 615 N. Wolfe St., Baltimore, MD 21205. Reprints: Dr. H. H. Garcia, Dept. de Microbiologia, Universidad Peruana Cayetano Heredia, Av. Honorio Delgado 430, Lima 31, Peru. * Members are listed after the text.

PY - 1997

Y1 - 1997

N2 - Neurocysticercosis is the main cause of acquired epilepsy in developing countries and is an emerging disease in the United States. Introduction of the immunoblot assay provided a new tool for the diagnosis and monitoring of neurocysticercosis. This study analyzed the relationship between clinical characteristics of cerebral infection (number and type of lesions) plus the baseline response on immunoblot and the changes observed after therapy. Reaction to all 7 diagnostic bands was associated with severe infection (more lesions). Seventeen patients (35%) had no active lesions on computed tomography (CT) 3 months after therapy and were considered cured. Although most cured patients remained seropositive after 1 year, 3 became seronegative before 9 months. In these 3 cases, the lesions had resolved on CT at 3 months. Persistent seropositivity does not necessarily indicate active infection. Serologic follow-up will be clinically helpful only in rare cases in which early antibody disappearance occurs.

AB - Neurocysticercosis is the main cause of acquired epilepsy in developing countries and is an emerging disease in the United States. Introduction of the immunoblot assay provided a new tool for the diagnosis and monitoring of neurocysticercosis. This study analyzed the relationship between clinical characteristics of cerebral infection (number and type of lesions) plus the baseline response on immunoblot and the changes observed after therapy. Reaction to all 7 diagnostic bands was associated with severe infection (more lesions). Seventeen patients (35%) had no active lesions on computed tomography (CT) 3 months after therapy and were considered cured. Although most cured patients remained seropositive after 1 year, 3 became seronegative before 9 months. In these 3 cases, the lesions had resolved on CT at 3 months. Persistent seropositivity does not necessarily indicate active infection. Serologic follow-up will be clinically helpful only in rare cases in which early antibody disappearance occurs.

UR - http://www.scopus.com/inward/record.url?scp=0031026717&partnerID=8YFLogxK

U2 - 10.1093/infdis/175.2.486

DO - 10.1093/infdis/175.2.486

M3 - Artículo

C2 - 9203680

AN - SCOPUS:0031026717

SN - 0022-1899

VL - 175

SP - 486

EP - 489

JO - Journal of Infectious Diseases

JF - Journal of Infectious Diseases

IS - 2

ER -

Serologic evolution of neurocysticercosis patients after antiparasitic therapy

Abstract

Bibliographical note

Access to Document

Other files and links

Fingerprint

Cite this